Intelligence Report · ~12 min read
Astellas Intelligence Report
Generated from 2 signals · 2 evidence sources
Type
Company Intelligence ReportGenerated
Jul 21, 2026
Confidence
High Confidence · 87%
Evidence
12 items
Sources
12
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Astellas maintains an active intelligence profile across Oncology, ADC, Bladder Cancer. 2 signals are linked with 1 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 87% across 2 tracked sources. Highest-priority development: FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer. Regulatory precedent. Why this matters: sets a approval precedent in the same sub-indication (bladder cancer) as Pfizer; the same agency is already in play for this signal, so precedent weight is higher.
Key Developments
Material intelligence events ranked by strategic relevance.
- investigateJul 11, 2026
FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Oncology · Bladder Cancer · opportunity score 28
View detail - regulatory
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Withdrawn | Cancer Accelerated Approvals
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — PADCEV (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — ONTRUZANT (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — INQOVI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — PADCEV (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 50 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: High. 1 investigate-priority signal warrant near-term portfolio review.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceWithdrawn | Cancer Accelerated Approvals
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — PADCEV (SUPPL)
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — ONTRUZANT (SUPPL)
Moderate Confidence · 77%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — INQOVI (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer
High Confidence · 95%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — PADCEV (SUPPL)
High Confidence · 86%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Approves PADCEV plus Keytruda for Muscle-Invasive Bladder Cancer Treatment
Oncology · Bladder Cancer
- FDA grants priority review for PADCEV supplemental application
Oncology · ADC